Literature DB >> 11724451

Quality of life in multiple sclerosis: the impact of depression, fatigue and disability.

M P Amato1, G Ponziani, F Rossi, C L Liedl, C Stefanile, L Rossi.   

Abstract

This study deals with the assessment of quality of life and its main clinical and demographical determinants in a clinical series of 103 patients with multiple sclerosis (MS) (37 men; 66 women; mean age 44.89 years; mean disease duration 12.40 years; mean EDSS score 4.07). We used the MSQOL-54 inventory, a disease-specific instrument recently validated in an Italian population. Each patient underwent a complete clinical assessment, including that of disability status (Expanded Disability Status Scale), cognitive function (Mini Mental State Examination), depression (Hamilton Rating Scale for Depression) and fatigue (Fatigue Severity Scale). In terms of Pearson's correlations, there was a moderate inverse relationship between disability level and the MSQOL-54 physical composite score, and a moderate to strong inverse correlation between depression or fatigue severity and both the physical and mental composite scores. In a stepwise linear regression analysis, depression, fatigue and disability level were confirmed to be significant and independent predictors of quality of life. Quality of life instruments can help to provide a broader measure of the disease impact and to develop a care program tailored to the patient's needs.

Entities:  

Mesh:

Year:  2001        PMID: 11724451     DOI: 10.1177/135245850100700511

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  125 in total

1.  Reliability and Validity of PROMIS Cognitive Abilities and Cognitive Concerns Scales Among People with Multiple Sclerosis.

Authors:  Heather Becker; Alexa Stuifbergen; Hwayoung Lee; Vicki Kullberg
Journal:  Int J MS Care       Date:  2014

2.  Psychometric properties of the Hamilton Depression Rating Scale in multiple sclerosis.

Authors:  Simona Raimo; Luigi Trojano; Daniele Spitaleri; Vittorio Petretta; Dario Grossi; Gabriella Santangelo
Journal:  Qual Life Res       Date:  2015-02-11       Impact factor: 4.147

Review 3.  A Taxonomy of Fatigue Concepts and Their Relation to Hearing Loss.

Authors:  Benjamin W Y Hornsby; Graham Naylor; Fred H Bess
Journal:  Ear Hear       Date:  2016 Jul-Aug       Impact factor: 3.570

4.  Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab: The ENER-G Study.

Authors:  Jeffrey Wilken; Robert L Kane; Cynthia L Sullivan; Mark Gudesblatt; Sylvia Lucas; Robert Fallis; Xiaojun You; Pam Foulds
Journal:  Int J MS Care       Date:  2013

5.  Aerobic exercise in people with multiple sclerosis: its feasibility and secondary benefits.

Authors:  Chad Swank; Mary Thompson; Ann Medley
Journal:  Int J MS Care       Date:  2013

Review 6.  Functional Electrical Stimulation Cycling Exercise for People with Multiple Sclerosis.

Authors:  Lara A Pilutti; Robert W Motl
Journal:  Curr Treat Options Neurol       Date:  2019-11-08       Impact factor: 3.598

Review 7.  The effect of deep brain stimulation on quality of life in movement disorders.

Authors:  A Diamond; J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

8.  Fatigue and physical disability in patients with multiple sclerosis: a structural equation modeling approach.

Authors:  Yvonne Bol; Annelien A Duits; Richel Lousberg; Raymond M M Hupperts; Michelle H P Lacroix; Frans R J Verhey; Johan W S Vlaeyen
Journal:  J Behav Med       Date:  2010-05-28

9.  Association of C-reactive protein and interleukin-6 with new-onset fatigue in the Whitehall II prospective cohort study.

Authors:  H J Cho; M Kivimäki; J E Bower; M R Irwin
Journal:  Psychol Med       Date:  2012-11-14       Impact factor: 7.723

10.  The impact of disability, fatigue and sleep quality on the quality of life in multiple sclerosis.

Authors:  Haleh Ghaem; Afshin Borhani Haghighi
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.